Company Overview of Takeda Pharmaceuticals International GmbH
Takeda Pharmaceuticals International GmbH, a pharmaceutical company, manufactures and markets patented products, branded generics, and over-the-counter products that treat patients in various therapeutic areas worldwide. It offers its products in the areas of cardiovascular and metabolic, oncology, central nervous system, respiratory and immunology, general medicine (gastrointestinal and genitourinary), and vaccines. The company also provides packaging, development, contract manufacturing, and quality control services. Takeda Pharmaceuticals International GmbH was formerly known as Nycomed International Management GmbH and changed its name to Takeda Pharmaceuticals International GmbH in Dece...
Founded in 1874
Key Executives for Takeda Pharmaceuticals International GmbH
Chief Executive Officer and President
Managing Director of Russia-Cis Business
Head of North Asia and Corporate Officer
Senior Vice President of Latin America
Head of Commercial Operations - Emerging Markets
Compensation as of Fiscal Year 2014.
Takeda Pharmaceuticals International GmbH Key Developments
Apricus Biosciences Launches Erectile Dysfunction Treatment in UK
Jun 16 14
Apricus Biosciences has launched an on-demand treatment for erectile dysfunction called Vitaros. The company announced that Vitaros will be marketed in the United Kingdom by Takeda Pharmaceuticals International GmbH. The erectile dysfunction market in the United Kingdom was approximately $200 million in 2013 based on prescription sales, making it one of the larger erectile dysfunction markets in Europe. The European PDE-5 inhibitor market is approximately $1.5 billion as estimated by IMS Health, and analyst estimates for ex-US Vitaros sales are in the range of $300 million at peak. Apricus announced that it had received multiple commercial product orders of Vitaros from its partners and is currently manufacturing multiple product batches through its contract manufacturer in Canada to support launches in Europe. The company announced that commercialization of Vitaros has been fully licensed to these partners, with Apricus positioned to earn tiered double-digit royalties and more than $200 million in potential milestone payments.
Takeda Pharmaceuticals International GmbH Receives European Commission Marketing Authorization for Entyvio (vedolizumab)
May 28 14
Takeda Pharmaceutical Company Limited announced that at its Takeda Pharmaceuticals International GmbH announced that the European Commission has granted marketing authorization for Entyvio (vedolizumab), a gut-selective humanized monoclonal antibody, and the first and only biologic therapy to be approved simultaneously for the treatment of adults with moderately to severely active ulcerative colitis (UC) and adults with moderately to severely active Crohn's disease who have had an inadequate response with, lost response to, or were intolerant to either conventional therapy or a tumor necrosis factor-alpha (TNF) antagonist. UC and CD are the two most common types of inflammatory bowel disease (IBD), affecting more than four million people worldwide, including approximately 2.2 million in Europe. Vedolizumab is now approved for marketing in the 28 member states of the European Union as well as Norway, Iceland and Liechtenstein. The marketing authorization application submission is supported by the GEMINITM Studies, a clinical program investigating vedolizumab in 2,700 patients across nearly 40 countries. It is phase 3 clinical trial program conducted to date evaluating both UC and CD patient populations in parallel. Enrolled patients had failed at least one conventional therapy, including corticosteroids, immuno modulators and/or a tumor necrosis factor-alpha (TNF) antagonist. TNF antagonist and conventional therapy failure patients included those with inadequate response (primary non-responders), loss of response (secondary non-responders) or those who were intolerant. Vedolizumab is also now approved for marketing in the United States, for the treatment of adult patients with moderately to severely active UC or CD.
Takeda Pharmaceuticals International GmbH Names Giles Platford as Head of Commercial Operations, Emerging Markets, with Effect from April 1, 2014
Mar 18 14
Takeda Pharmaceuticals International GmbH announced that Giles Platford has been appointed Head of Commercial Operations, Emerging Markets, reporting to Christophe Weber, Chief Operating Officer of Takeda Pharmaceutical Company Limited as of April 1, 2014. In this role he will be responsible for leading the continued expansion of Takeda's commercial activities in this region, which comprises Russia-CIS, Latin America, Middle East/Africa and South Asia. A UK national, Platford has been with Takeda since 2009. Most recently, he served as Head of the Middle East, Turkey, Africa (META) region. Prior to this, Platford was General Manager of Takeda Brazil, where he led the successful acquisition of Multilab, a mid-sized company focused on branded generics and over-the-counter (OTC) products, positioning Takeda as one of the top 10 pharmaceutical groups in Brazil.
Similar Private Companies By Industry
Recent Private Companies Transactions
|No transactions available in the past 12 months.|